Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Safety and Persistence of Effectiveness of Manualized MDMA-Assisted Therapy for PTSD
2021-005596-39Phase 2Terminated
- Sponsor
- MAPS Europe B.V.
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of midomafetamine in post-traumatic stress disorder (PTSD) (2 arms), sponsored by MAPS Europe B.V. Primary endpoint: CAPS-5 total score at long-term follow-up (Visit 1). Started Mar 2022; status: terminated.
02
Drugs
midomafetamine
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on 2021-005596-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005596-39.